FGF1: A "potential new star" in the field of diabetes treatment

FGF1: A "potential new star" in the field of diabetes treatment

At a time when diabetes is rampant, finding more effective treatments has always been an important topic in the medical community. Recently, a research result on FGF1 has brought new hope to diabetic patients.

Diabetes, especially type 2 diabetes, is spreading around the world at an alarming rate, bringing a heavy health burden to countless patients. Although the commonly used insulin sensitizer TZDs can lower blood sugar, the side effects should not be underestimated. Problems such as weight gain, bone loss and congestive heart failure make patients miserable. Therefore, scientists have been eager to find safer and more effective treatment options.

FGF1, a research hotspot that has attracted much attention in the field of diabetes and obesity treatment, has gradually come into people's view. The FGF family is a research hotspot in the field of diabetes and obesity treatment, and FGF1 stands out with its unique blood sugar-lowering effect.

In the experiment, the researchers injected FGF1 into the brains of mice and rats with type 2 diabetes once, and a magical thing happened: the blood sugar levels of these animals remained normal for at least the next 4 months. Moreover, this lasting anti-diabetic effect is not affected by food intake or body weight, that is, blood sugar can be effectively controlled even without losing weight. This discovery undoubtedly opens up a new path for diabetes treatment.

FGF1 is actually a member of the FGF family, which is a hot research topic in the field of diabetes and obesity treatment. FGF21 has attracted much attention because of its clear hypoglycemic and weight-reducing activities. And FGF1 also has a unique charm. Under physiological conditions, the content of FGF1 in the circulation is very small, but studies have found that endocrine FGF1 has hypoglycemic activity and is a potential insulin sensitizer.

In genetic and diet-induced insulin resistance mouse models, a single injection of recombinant FGF1 protein can effectively reduce blood sugar levels. The hypoglycemic effect is FGF1 dose-dependent, and no hypoglycemic events occur at the maximum dose. Moreover, it has no effect on mice with normal blood sugar levels, indicating that its hypoglycemic effect is dependent on blood sugar levels. What is even more surprising is that long-term use of recombinant FGF1 protein can not only significantly improve blood sugar, insulin resistance and liver metabolism, but also has no side effects similar to TZDs drugs.

What is more worth mentioning is that the researchers found a truncation that can distinguish the cell proliferation activity and hypoglycemic activity of FGF1. The FGF1 truncation with 24 amino acids at the N-terminus, while retaining the hypoglycemic activity, significantly reduced the mitotic activity, which greatly reduced the potential safety risks.

Although the current research is still in the animal experiment stage, and the specific mechanism of FGF1's role in the brain is not yet fully understood, its long-lasting anti-diabetic effect shown in mouse and rat experiments has undoubtedly laid a solid foundation for clinical application.

The characteristics of FGF1's safe and effective hypoglycemic effect make it a popular candidate for the new generation of hypoglycemic drugs. The characteristics of cell proliferation activity and hypoglycemic activity that can be clearly distinguished have further promoted the possibility of its clinical application. Although there is still a long way to go from the laboratory to the clinic, FGF1 has undoubtedly opened a new door for diabetes treatment. We have reason to believe that with the continuous deepening of research, FGF1 is expected to become a blessing for diabetic patients and bring new possibilities for their healthy life.